patient
chronic
kidney
diseas
ckd
increas
cardiovascular
cv
risk
account
overal
mortal
previou
studi
found
independ
associ
lower
level
estim
glomerular
filtrat
rate
gfr
risk
cv
diseas
death
cv
event
hospit
risk
evid
estim
gfr
increas
estim
gfr
mechan
contribut
pathogenesi
cv
diseas
ckd
complex
includ
tradit
nontradit
cv
risk
factor
nonetheless
well
known
enhanc
activ
system
ra
among
other
play
major
role
progress
cardiac
renal
injuri
within
ra
angiotensinconvert
enzym
ace
convert
angiotensin
ang
vasoconstrictor
angii
mediat
effect
predominantli
angiotensin
type
receptor
respons
pathophysiolog
effect
ra
angii
increas
blood
pressur
contribut
cardiac
remodel
fibrosi
inflamm
thrombosi
plaqu
ruptur
enzym
cleav
ctermin
amino
acid
angii
gener
peptid
identifi
act
via
ma
receptor
counteract
advers
effect
angii
previou
experiment
studi
report
downregul
lead
agedepend
develop
glomerular
mesangi
expans
acceler
progress
glomerulosclerosi
tubular
injuri
macrophag
infiltr
interstiti
fibrosi
integr
cell
membran
protein
undergo
cleavag
shed
releas
catalyt
activ
ectodomain
circul
initi
studi
larg
cohort
abl
detect
circul
activ
subject
lower
ace
interestingli
subject
detect
older
without
higher
preval
cv
diseas
diabet
hypertens
suggest
may
upregul
subject
cv
diseas
counteract
advers
effect
angii
subsequ
studi
demonstr
circul
activ
could
also
detect
healthi
subject
solubl
activ
increas
heart
failur
patient
acut
myocardi
infarct
correl
sever
heart
diseas
circul
level
increas
patient
type
diabet
vascular
complic
group
also
demonstr
circul
activ
measur
kidney
transplant
patient
kt
suggest
may
use
noninvas
marker
understand
role
ra
kt
recent
robert
et
al
show
plasma
activ
lower
patient
undergo
haemodialysi
predialysi
patient
ckd
howev
circul
activ
studi
ckd
patient
without
previou
histori
cv
event
therefor
aim
studi
determin
level
circul
ace
activ
ckd
patient
without
histori
cv
diseas
determin
factor
associ
circul
ace
activ
popul
total
subject
observ
multicentr
studi
nefrona
project
recruit
octob
june
studi
male
femal
patient
without
histori
cv
diseas
angina
pectori
acut
myocardi
infarct
ischaem
stroke
haemorrhag
stroke
abdomin
aortic
aneurysm
atherosclerosi
age
rang
year
includ
studi
exclus
criteria
pregnanc
human
immunodefici
viru
infect
type
transplant
histori
transplant
previou
histori
carotid
arteri
diseas
patient
activ
infect
andor
hospit
last
month
intercurr
ill
presum
absenc
followup
surviv
expect
less
year
patient
classifi
three
group
accord
gfr
modif
diet
renal
diseas
mdrd
nondialysi
patient
ckd
stage
dialysi
haemodialysi
periton
dialysi
patient
subject
use
control
cont
clinic
variabl
analys
gender
age
histori
diabet
hypertens
dyslipidemia
smoke
activ
smoker
last
month
angiotensinconvert
enzym
inhibitor
acei
angiotensin
receptor
blockad
arb
diabet
medic
insulin
oral
antidiabet
drug
vitamin
analogu
treatment
record
analyt
variabl
analys
glycaem
blood
glucos
glycosyl
haemoglobin
lipid
anaemia
profil
presenc
plaqu
determin
ultrasound
carotid
arteri
ethylenediaminetetraacet
acid
edta
anticoagul
plasma
sampl
collect
patient
control
centrifug
g
frozen
analysi
protocol
review
approv
ethic
review
board
hospit
particip
sign
inform
consent
document
includ
studi
fluoresc
enzymat
assay
protocol
perform
previous
describ
group
use
fluoresc
substrat
mcaalaproli
dnp
oh
biomol
enzo
life
scienc
plasma
sampl
collect
tube
contain
edta
chelat
agent
loos
bound
metal
ion
act
cofactor
carboxypeptidas
edta
inhibit
ace
activ
zinc
chlorid
ad
plasma
sampl
avoid
bound
briefli
plasma
incub
buffer
mm
trishcl
mm
nacl
ph
presenc
proteas
inhibitor
captopril
amastatin
bestatin
zproprolin
presenc
differ
concentr
mm
figur
sampl
incub
quench
fluoresc
substrat
reaction
buffer
final
volum
h
optim
concentr
determin
activ
mm
activ
also
calcul
serum
sampl
subject
previous
describ
perform
standard
curv
recombin
human
calbiochem
ad
increas
quantiti
ng
figur
set
experi
serum
edtaplasma
sampl
incub
presenc
absenc
experi
carri
duplic
result
express
plasmahour
ace
fluoresc
enzymat
assay
perform
previous
describ
modif
test
find
optim
concentr
revers
effect
edta
briefli
plasma
differ
concentr
mm
figur
incub
appropri
buffer
borat
buffer
nhippurylhisleu
hhl
min
final
fluoresc
adduct
enzymecatalys
product
lhistidyllleucin
quantifi
concentr
mm
found
optim
detect
ace
ace
activ
also
calcul
heparinplasma
serum
sampl
subject
previous
describ
experi
carri
duplic
result
express
plasma
normal
continu
variabl
assess
normal
probabl
plot
variabl
express
mean
se
pair
casecontrol
studi
perform
cont
versu
pair
cont
versu
pair
versu
pair
equal
distribut
gender
diabet
hypertens
dyslipidemia
smoke
habit
weight
kg
age
year
continu
variabl
evalu
nonparametr
test
bivari
correl
calcul
spearman
correl
coeffici
anova
use
among
plasma
ace
activ
intraclass
correl
coeffici
icc
use
determin
concord
assay
differ
human
sampl
multipl
linear
regress
analys
use
natur
logarithm
transform
plasma
ace
activ
carri
identifi
independ
predictor
enzymat
activ
spss
version
window
use
statist
calcul
r
packag
version
use
casecontrol
studi
p
consid
statist
signific
total
patient
includ
studi
circul
ace
activ
measur
cont
subject
ckd
patient
without
previou
histori
cv
diseas
divid
requir
dialysi
dialysi
characterist
studi
subject
shown
tabl
patient
younger
thinner
patient
higher
preval
hypertens
dyslipidemia
cont
nefrona
first
larg
studi
describ
actual
preval
subclin
atheromatosi
across
differ
ckd
stage
baselin
atherosclerosi
paramet
patient
detail
arroyo
et
al
studi
ace
activ
edtaplasma
sampl
purpos
ace
activ
measur
differ
condit
edtaplasma
sampl
edtaplasma
sampl
ad
serum
sampl
plasma
sampl
collect
heparin
subject
found
strong
correl
icc
differ
studi
sampl
plasma
heparin
serum
ace
activ
addit
abl
recov
activ
ace
activ
edtaplasma
ad
assay
tabl
concord
nondetect
activ
observ
edtaplasma
sampl
ad
edtaplasma
activ
observ
figur
expect
ad
edtaplasma
activ
detect
result
demonstr
within
edtaplasma
neither
endogen
exogen
activ
detect
howev
addit
zinc
reaction
abl
recov
enzymat
activ
circul
activ
significantli
decreas
compar
cont
versu
p
compar
cont
versu
p
addit
significantli
decreas
compar
versu
p
figur
howev
pair
casecontrol
studi
perform
differ
found
p
figur
therefor
analys
group
separ
male
significantli
increas
activ
compar
femal
studi
group
p
furthermor
patient
plaqu
also
increas
activ
compar
without
plaqu
p
tabl
cont
diabet
show
increas
circul
activ
compar
nondiabet
patient
p
p
howev
differ
observ
dialysi
patient
p
hypertens
also
associ
increas
activ
cont
p
tabl
patient
dyslipidemia
show
increas
level
circul
cont
p
p
differ
found
p
interestingli
smoker
significantli
increas
circul
activ
compar
nonsmok
p
tabl
found
signific
direct
correl
age
glycosyl
haemoglobin
cont
p
p
addit
direct
correl
age
found
p
circul
activ
significantli
increas
cont
arb
therapi
compar
nontreat
patient
p
treatment
acei
influenc
circul
tabl
activ
also
increas
cont
p
p
oral
antidiabet
agent
compar
nontreat
addit
insulin
therapi
increas
activ
p
tabl
surprisingli
circul
decreas
treat
cholecalciferol
compar
nontreat
patient
p
tabl
multivari
linear
regress
analysi
tabl
male
gender
advanc
age
identifi
independ
predictor
circul
activ
studi
group
diabet
also
identifi
independ
predictor
activ
addit
arb
cholecalciferol
therapi
independ
predictor
circul
ace
activ
significantli
increas
compar
cont
versu
p
compar
cont
versu
p
addit
ace
activ
significantli
increas
compar
versu
p
figur
concord
pair
casecontrol
studi
perform
result
observ
figur
femal
increas
circul
ace
activ
compar
male
cont
p
howev
differ
observ
p
tabl
cont
presenc
plaqu
show
decreas
level
circul
ace
activ
compar
without
plaqu
p
howev
differ
observ
ace
activ
decreas
hypertens
dyslipidemia
compar
nonhypertens
p
without
dyslipidemia
p
tabl
found
signific
indirect
correl
circul
ace
activ
age
p
glycosyl
haemoglobin
p
cont
increas
ace
activ
found
cont
arb
therapi
compar
nontreat
patient
expect
subject
treat
acei
lower
level
ace
activ
compar
nontreat
subject
group
ace
activ
decreas
treat
cholecalciferol
compar
nontreat
tabl
multipl
regress
analysi
tabl
femal
gender
younger
age
identifi
independ
predictor
circul
ace
activ
cont
diabet
also
identifi
independ
predictor
circul
ace
activ
well
bivari
analysi
acei
therapi
invers
associ
ace
activ
studi
group
furthermor
cholecalciferol
treatment
found
independ
predictor
ace
activ
arb
therapi
identifi
independ
predictor
circul
ace
activ
cont
present
studi
demonstr
circul
ace
activ
may
measur
human
edtaplasma
first
studi
show
circul
activ
decreas
dialysi
patient
without
previou
histori
cv
diseas
addit
also
show
correl
classic
cv
risk
factor
name
male
gender
advanc
age
diabet
male
gender
advanc
age
enzymat
activ
wide
studi
renal
heart
tissu
physiolog
patholog
condit
howev
studi
assess
human
circul
activ
major
measur
activ
serum
heparin
blood
sampl
previous
measur
circul
activ
serum
kt
acut
myocardi
infarct
patient
initi
abl
measur
activ
edtaplasma
sampl
chelat
agent
edta
complet
inhibit
tissu
solubl
secret
chines
hamster
ovari
cell
media
activ
chelat
zinc
ion
requir
metalloproteas
activ
henc
made
effort
measur
activ
edtaplasma
sampl
demonstr
ad
zinc
chlorid
subsequ
avoid
edta
chelat
effect
ace
activ
could
measur
robert
et
al
demonstr
plasma
activ
decreas
dialysi
patient
patient
male
gender
diabet
associ
increas
ra
blockad
affect
circul
howev
studi
sampl
size
small
healthi
subject
use
comparison
contemporan
ckd
patient
present
studi
larger
sampl
size
n
contemporan
studi
group
note
studi
patient
histori
cv
diseas
agreement
robert
et
al
initi
found
circul
activ
decreas
dialysi
patient
expect
measur
circul
pre
postdialysi
show
differ
data
shown
demonstr
enzym
remov
dialysi
one
surmis
haemodialysi
could
alter
level
activ
plasma
owe
larg
molecular
size
studi
dialysi
patient
younger
control
group
pair
casecontrol
studi
perform
differ
among
ckd
group
observ
suggest
decreas
within
dialysi
patient
may
ascrib
age
within
cont
signific
differ
level
circul
activ
demonstr
male
femal
result
confirm
work
other
show
circul
sex
depend
higher
level
male
data
anim
model
suggest
solubl
shed
stimul
tumour
necrosi
convertas
possibl
increas
male
may
relat
increas
shed
studi
focus
axi
gender
differ
need
confirm
premis
mani
studi
associ
circul
activ
higher
risk
cv
diseas
epelman
et
al
previous
demonstr
circul
activ
elev
patient
diagnosi
heart
failur
recent
studi
group
show
activ
upregul
acut
phase
stelev
myocardi
infarct
correl
infarct
size
furthermor
kt
patient
previou
histori
ischaem
heart
diseas
present
increas
activ
soropaavonen
et
al
demonstr
circul
increas
patient
diabet
decreas
egfr
vascular
complic
cv
diseas
concord
studi
demonstr
activ
also
increas
diabet
ckd
patient
correl
glycosyl
haemoglobin
mice
experiment
diabet
activ
increas
renal
cortex
circul
suggest
potenti
mechan
adapt
diabetesassoci
angii
overact
circul
activ
increas
start
earli
stage
diabet
correl
gfr
measur
activ
may
becom
new
biomark
cv
diseas
ckd
circul
ace
activ
increas
without
previou
histori
cv
diseas
demonstr
ace
activ
correl
classic
cv
risk
factor
male
advanc
age
diabet
expect
acei
therapi
invers
associ
ace
activ
group
concord
result
studi
found
lower
level
circul
ace
subject
histori
hypertens
higher
level
diabet
patient
renal
complic
howev
studi
found
relationship
circul
ace
classic
cv
risk
factor
surmis
incongru
observ
studi
popul
may
ascrib
effect
ra
blockad
circul
ace
ethic
reason
ra
blockad
agent
stop
studi
conclus
studi
show
circul
ace
activ
recov
detect
human
edtaplasma
sampl
ad
zinc
chlorid
addit
activ
directli
correl
classic
cv
risk
factor
male
gender
diabet
older
age
find
may
therapeut
implic
cv
diseas
help
delay
progress
ckd
prospect
studi
short
longterm
followup
help
us
elucid
role
biomark
ckd
